Clinical trials: Immune System Disease
Multiple Sclerosis
Prospective Longitudinal Monocentric Study to Evaluate the Syde® Digital Endpoint in Patients With Multiple Sclerosis
The study aims to assess the validity of real-world activity monitoring by the Syde® wearable device in subjects with multiple slclerosis.
- Trial name
- NHS-MS-EGYPT (NCT06346704)
- Testing
- Digital HealthTechnology
- Where
- Egypt
- Volunteers
- 86 people
- Sponsor
- SYSNAV
Multiple Myeloma, Neoplasm, Plasma Cell
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
This study will find the maximum tolerated dose (MTD) of CYNK-001 which contain NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given post Autologous Stem Cell Transplant (ASCT).
- Conditions
- Multiple Myeloma, Neoplasm, Plasma Cell, Neoplasms by Histologic Type, Neoplasms
- Trial name
- NCT04309084
- Testing
- CYNK-001
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Celularity Incorporated
Arthritis, Rheumatoid
A Placebo-Controlled, Double-Blinded, Randomized Trial of Remicade in Korean Patients With Rheumatoid Arthritis Despite Methotrexate (Study P04280)(COMPLETED)
Prior to the first infusion, patients will be randomized into one of two groups (placebo or infliximab). All patients will continue to receive the same does of methotrexate (MTX) during the study as received prior to the study.
- Trial name
- NCT00202852
- Testing
- MTX, Infliximab
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections, Hepatic Insufficiency
A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions
The objective of this study was to evaluate the steady-state clearance of nevirapine among HIV-1 positive patients with hepatic fibrosis, and to examine whether the degree of hepatic impairment influences clearance.
- Trial name
- NCT00144248
- Testing
- nevirapine
- Where
- 8 sites in United States, France and 1 more
- Volunteers
- 51 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents
First-line antiretroviral regimens are highly efficacious and generally well tolerated. However, as these regimens need to be taken life-long, there is growing concern about long-term toxicities associated with these regimens.
- Trial name
- NCT03682848
- Testing
- DTG + 3TC FDC
- Where
- 8 sites in Kenya, South Africa and 1 more
- Volunteers
- 32 people
- Sponsor
- ViiV Healthcare
HIV Infections
Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults
Study to determine the effects of 28 days of nevirapine treatment on the steady-state pharmacokinetics of amprenavir and of abacavir and to further evaluate the pharmacokinetics of nevirapine in combination with amprenavir and…
- Trial name
- NCT02182765
- Testing
- Nevirapine, Amprenavir, Abacavir
- Volunteers
- 8 people
- Sponsor
- Boehringer Ingelheim
Asthma
Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults
This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA-MDI (E004), using a stable isotope deuterium-labeled epinephrine (epinephrine-d3) to differentiate the…
- Trial name
- NCT01737892
- Testing
- Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation, Arm C-Epinephrine Inhalation Aerosol CFC
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma
Online Asthma Self-Management for Children Aged 5-10 and Their Parents
The potential benefits of this research to public health include improved understanding of cultural factors in pediatric asthma self-management, improved self-management skills for children, and better asthma management skills…
- Trial name
- ChildAsthma (NCT02602392)
- Testing
- Lungtropolis, Asthma educational booklet
- Where
- United States
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- Oregon Center for Applied Science, Inc.
Autoimmune Diseases
Phase 0 Microdose Study
This study is a methodology study to evaluate a microdose strategy for Drug-Drug Interaction (DDI) which will be useful in the evaluation of the backup compounds for GSK706769, as well as possibly other assets.
- Trial name
- NCT00975936
- Testing
- [14C]-GSK706769, Ketoconazole
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Juvenile Idiopathic Arthritis
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study
This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 core study.
- Trial name
- NCT01667471
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 3 sites in Germany
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Relapsed or Refractory Multiple Myeloma (RRMM)
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing F182112 with Standard of Care in Patients with Relapsed or Refractory Multiple Myeloma
- Trial name
- NCT07579234
- Testing
- F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd)
- Where
- China
- Volunteers
- 261 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Multiple Sclerosis
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
This study assessed the safety, tolerability and efficacy of two doses of oral fingolimod compared to placebo on efficacy parameters in patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- FREEDOMS II (NCT00355134)
- Testing
- Fingolimod
- Where
- 112 sites in United States, Australia and 6 more
- Volunteers
- 1,083 people
- Sponsor
- Novartis
Adult T-cell Leukemia-Lymphoma
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
The purpose of this study is to estimate the overall response rate of subjects with relapsed or refractory Adult T-cell Leukemia-Lymphoma (ATL).
- Trial name
- NCT01626664
- Testing
- KW-0761, Pralatrexate, gemcitabine plus oxaliplatin
- Where
- 20 sites in United States, Belgium and 4 more
- Volunteers
- 71 people
- Sponsor
- Kyowa Kirin, Inc.
Ankylosing Spondylitis, Psoriatic Arthritis
Study Evaluating Epidemiology of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in Australia
The study is a cross sectional, epidemiology study of disease severity for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in four geographic regions in Australia (Illawarra, Sutherland, Hunter Urban and…
- Conditions
- Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis
- Trial name
- NCT00751387
- Where
- 4 sites in Australia
- Volunteers
- 559 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Type 1 Diabetes
Hybrid Closed Loop System for Patients on Multiple Daily Insulin Injections
The objective of this study is to assess structured group education onboarding protocol of the 670 G Hybrid Closed Loop (HCL) systems in achieving glucose control of patients on Multiple Daily Insulin Injections (MDI).
- Trial name
- NCT04145804
- Testing
- Medtronic Minimed 670G insulin pump
- Where
- Qatar
- Volunteers
- 40 people
- Sponsor
- Hamad Medical Corporation
Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL
Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL
- Conditions
- Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent, Mantle Cell Lymphoma Refractory, Small Lymphocytic Lymphoma, Relapsed
- Trial name
- NCT05360238
- Testing
- MB-106
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- Mustang Bio
Primary Immunodeficiency Diseases (PID)
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
The purpose of the study is to determine the feasibility of infusing a full 4-week dose of Immune Globulin Intravenous (Human), 10% in a single subcutaneous site and the amount of recombinant human hyaluronidase needed to infuse…
- Trial name
- NCT00782106
- Testing
- Recombinant human hyaluronidase + immune globulin intravenous
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Baxalta now part of Shire
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Eosinophilic Esophagitis
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in…
- Trial name
- EOS-4 (NCT06596252)
- Testing
- Budesonide
- Where
- 21 sites in United States, Spain
- Volunteers
- 308 people
- Sponsor
- Dr. Falk Pharma GmbH
Multiple Sclerosis
WOE of Anti-CD20 Therapies
The nature, intensity, and prevalence of this wearing-off effect remain poorly understood. To our knowledge, there is no consensus in the literature on what symptoms constitute a wearing-off effect, nor is there a single…
- Trial name
- NCT06121349
- Testing
- ocrelizumab, ofatumumab
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.